JN Biosciences LLC

Bridging Science to Life

JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043

  • Home
  • ManagementClick to open the Management menu
    • Naoya Tsurushita, Ph.D.
    • J Yun Tso, Ph.D.
  • Technology
  • PipelineClick to open the Pipeline menu
    • CD122
    • Death Receptors
    • Costimulatory Molecules
    • Checkpoint Molecules
    • Bispecific antibodies
  • Humanization
  • Partnering
  • NewsClick to open the News menu
    • 2022
    • 2021
    • 2019 - 2020
    • 2018
    • 2017
    • 2016
    • 2012 - 2015
  • Contact

2017

September 8, 2017

A Japanese patent (6205363) was issued for JN Biosciences' MultYmab™ antibody engineering technology.  This patent covers multimeric antibodies and Fc fusion proteins generated by the MultYmab™ technology that bind to and crosslink surface molecules and induce intracellular signaling.  

May 12 - 16, 2017

Therapeutic efficacy of an anti-CD122 IgG antibody in the mouse model of type I diabetes was presented by Dr. Wenxian Fu's group of University of California at San Diego at the American Association of Immunologists Meeting in Washington D.C. (click here for the abstract).

The efficacy of an anti-CD122 IgG antibody for treatment of vitiligo in the mouse model was presented by Dr. John Harris' group of University of Massachusetts at the American Association of Immunologists Meeting in Washington D.C. (click here for the abstract).

March 19 - 23, 2017

The data showing the biological activity of AB154, a humaized anti-TIGIT IgG1  monoclonal antibody, which is expected to induce a strong anti-cancer immune response in humans, was presented at the Keystone Symposia - Cancer Immunology and Immunotherapy in Whistler, British Columbia, Canada (click here for the abstract).

January 10, 2017

A new U.S. patent (9,540,442) was issued for JN Biosciences' MultYmab™ antibody engineering technology, which has been used for generation of an alternative form of hexameric IgG antibodies that function as potent agonists against costimulatory molecules for cancer immunotherapy.   


 

Copyright 2022 JN Biosciences. All rights reserved.

 

JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043